Navigation Links
According to Surveyed U.S. Oncologists, Zytiga is the Patient-Share Leader in First-Line Metastatic Castrate-Resistant Prostate Cancer
Date:9/25/2013

EXTON, Pa., Sept. 25, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that, according to oncologists surveyed in Q3 2013, Johnson & Johnson/Janssen Biotech/Janssen-Cilag's Zytiga is the patient-share leader in the first-line asymptomatic and symptomatic metastatic castrate-resistant prostate cancer (mCRPC) settings; respondents in Q1 2013 cited conventional hormone therapy and docetaxel as lead therapies in these respective settings. Surveyed oncologists in Q3 2013 reported that Medivation/Astellas Pharma's Xtandi holds the most patient shares in the second- and third-line mCRPC settings. The findings are from the TreatmentTrends® Prostate Cancer (US) Q3 2013 report, in which 50 urologists and 51 medical oncologists were surveyed about their current and expected treatment practices for prostate cancer.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36805LOGO)

The report also finds that most surveyed physicians expressed a high level of satisfaction with Zytiga and Xtandi as treatment options for mCRPC. Notably, one-third of respondents also expressed high satisfaction with Algeta/Bayer HealthCare's Xofigo. Consistent with previous waves of research, Dendreon's Provenge and mitoxantrone are associated with the lowest levels of overall satisfaction, according to surveyed physicians.

"The market entry of multiple agents that have prolonged overall survival in pivotal Phase III studies has created an urgent need to understand the optimal sequence in which these therapies should be given," said Decision Resources Group Senior Business Insights Analyst Khurram Nawaz, M.Sc. "When considering the sequence of therapies for mCRPC, the majority of surveyed physicians agreed that they would switch to an agent with a different mechanism of action upon disease progression, use novel hormonal agents before chemotherapy and delay use of chemotherapy for as long as possible."

TreatmentTrends® Prostate Cancer is a syndicated report designed to provide a view of the current and future management of prostate cancer based on primary research fielded with 50 urologists and 50 medical oncologists in the United States. The report evaluates treatment and diagnosis patterns of the disease and physician opinions on possible future therapy options. BioTrends is also covering the launch of Xtandi and Xofigo through its LaunchTrends® studies.

About BioTrends Research Group
BioTrends Research Group provides syndicated and custom primary market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets. For information on BioTrends publications and research capabilities, please visit www.bio-trends.com. BioTrends is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks of their respective holders.

For more information, contact:

Decision Resources Group
Christopher Comfort
781-993-2597
ccomfort@dresources.com


'/>"/>
SOURCE BioTrends Research Group
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. In Terms of Effect on Overall Survival, Current and Emerging Therapies Have No Advantage Over Avastin/FOLFIRI in the Treatment of Second-Line Metastatic Colorectal Cancer, According to Clinical Data and Thought Leader Opinion
2. Rising Drug Resistance is Driving Early-Line Use of Powerful Antibiotics Such as Carbapenems for Gram-Negative Infections, According to Surveyed EU5 Physicians
3. Annual Healthcare Cost for a Typical American Family is $22,030 According to 2013 Milliman Medical Index
4. Type 2 Diabetes Control Worsening, According To Study Of Patients On Commercial Insurance
5. Fewer Venture Capital Dollars Invested Into Life Sciences Companies In Q1 2013, According To The MoneyTree Report
6. Food Recalls Driven by Companies Issuing Multiple Recalls in the First Quarter of 2013, According to Latest ExpertRECALL Index
7. Nearly 8 Million Healthcare Personnel Come in Contact with Chemotherapy Drugs, According to CDC
8. Recreational Marijuana Users More Likely To Misuse Prescription Drugs, According to National Study by Quest Diagnostics
9. Prescription Drug Misuse Remains at Alarming Levels, According to National Study by Quest Diagnostics
10. Despite the Recent Availability of Xtandi, Zytiga Continues to Dominate the Second-Line Metastatic Castrate-Resistant Prostate Cancer Setting, According to Surveyed U.S. Oncologists and Urologists
11. Hologics 3D Mammography Technology to be the "New Standard of Care," According to Healthcare Research Firm KLAS
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... LAWRENCE, Mass. , May 24, 2016  NxStage ... medical technology company focused on advancing renal care, today ... Officer, plans to participate in the following schedule of ... will be made available at http://ir.nxstage.com/ . ... Jefferies Healthcare Conference NY, NY           Friday, ...
(Date:5/24/2016)... May 24, 2016  Joe Marziani has joined VMS BioMarketing as senior vice president ... today. In his new role, Marziani will lead the company,s business development and sales ... improve outcomes. Photo - http://photos.prnewswire.com/prnh/20160523/371089 ... ... ...
(Date:5/24/2016)... , May 24, 2016 ... doble terapia del mundo, introduce catéteres para la ... OrbusNeich, una compañía global especializada en el ... ha expandido su cartera incluyendo productos para tratar ... y Scoreflex™ PTA son los dispositivos de primera ...
Breaking Medicine Technology:
(Date:5/24/2016)... ... May 24, 2016 , ... ... Cifolelli has joined the company as Vice President of Sales. Cifolelli’s primary ... and international sales in the rapidly expanding field of organizational social engineering. ...
(Date:5/24/2016)... ... May 24, 2016 , ... i2i, ... identity and website at its “Transforming Outcomes” User Conference in Las Vegas on ... i2i’s ongoing success to set the market standard for meaningful population health management. ...
(Date:5/24/2016)... ... May 24, 2016 , ... Educational opportunities, ... housing, with more advantaged communities providing richer opportunities. Recognizing the key role of ... school improvement policies; (b) school choice policies; (c) school desegregation policies; (d) wealth-focused ...
(Date:5/24/2016)... Georgia (PRWEB) , ... May 24, 2016 , ... Mental ... 1969 by the Church of Scientology and renowned professor of psychiatry Thomas Szasz, is ... of its “Psychiatry: An Industry of Death” exhibit in Atlanta, Georgia. The opening of ...
(Date:5/24/2016)... NY (PRWEB) , ... May 24, 2016 , ... ... treatment for physical disease or injury that focuses on repairing the musculoskeletal and ... , With an emphasis on functional restoration, NYDNRehab began providing treatments for physical ...
Breaking Medicine News(10 mins):